Ask AI
ProCE Banner Activity

Ottimizzazione del trattamento del linfoma mantellare: Linee guida basate su casi concreti, elaborate da esperti dell'UE

PDF

Questo modulo fornisce le prospettive di esperti dell'UE sull'algoritmo di trattamento attuale, sulle linee guida e sugli approcci basati sull'evidenza, per l'integrazione ottimale dei trattamenti disponibili nei pazienti con linfoma mantellare (MCL), tenendo in considerazione l'età del paziente, il livello di fitness, la presenza di fattori di rischio, le comorbidità preesistenti e le terapie farmacologiche concomitanti.

Released: June 12, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for global hematology/oncology physician specialists and other healthcare professionals providing care for patients with mantle cell lymphoma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan BTK inhibitor-based combination strategies for patients with treatment-naïve MCL, considering new indications, expert recommendations, and available efficacy and safety evidence  

  • Select chemotherapy-free treatment strategies for appropriate patients with MCL

  • Manage treatment-related adverse events associated with targeted therapies alone or in combination to extend duration on treatment and improve clinical outcomes

Financial Disclosures

Primary Author

Mats Jerkeman, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Galapagos, Johnson & Johnson, Kite, Lilly, Sobi.